{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T03:04:47Z","timestamp":1779937487729,"version":"3.53.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"DOI":"10.1186\/s12905-026-04440-z","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T23:23:19Z","timestamp":1775690599000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictive value of serial dynamic lipid monitoring for pathologic complete response to neoadjuvant chemotherapy in luminal breast cancer: a retrospective study integrating metabolic and clinical indicators"],"prefix":"10.1186","volume":"26","author":[{"given":"Yi","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"issue":"9","key":"4440_CR1","doi-asserted-by":"publisher","first-page":"6171","DOI":"10.1007\/s00432-023-04588-3","volume":"149","author":"K Alsaleh","year":"2023","unstructured":"Alsaleh K, Al Zahwahry H, Bounedjar A, et al. Neoadjuvant endocrine therapy with or without palbociclib in low-risk patients: a phase III randomized double-blind SAFIA trial. J Cancer Res Clin Oncol. 2023;149(9):6171\u20139. https:\/\/doi.org\/10.1007\/s00432-023-04588-3.","journal-title":"J Cancer Res Clin Oncol"},{"key":"4440_CR2","doi-asserted-by":"publisher","unstructured":"Di Leone A, Franco A, Castagnetta V, et al. Personalizing neoadjuvant chemotherapy: the impact of BRCA variants on pathologic complete response in luminal B breast cancer. Cancers (Basel). 2025;17(10):1619. Published 2025 May 10. https:\/\/doi.org\/10.3390\/cancers17101619","DOI":"10.3390\/cancers17101619"},{"key":"4440_CR3","doi-asserted-by":"publisher","first-page":"100974","DOI":"10.1016\/j.drup.2023.100974","volume":"69","author":"Z Zhu","year":"2023","unstructured":"Zhu Z, Shen H, Xu J, et al. GATA3 mediates doxorubicin resistance by inhibiting CYB5R2-catalyzed iron reduction in breast cancer cells. Drug Resist Updat. 2023;69:100974. https:\/\/doi.org\/10.1016\/j.drup.2023.100974.","journal-title":"Drug Resist Updat"},{"key":"4440_CR4","doi-asserted-by":"publisher","first-page":"102669","DOI":"10.1016\/j.ctrv.2023.102669","volume":"123","author":"L Cantini","year":"2024","unstructured":"Cantini L, Trapani D, Guidi L, et al. Neoadjuvant therapy in hormone receptor-positive\/HER2-negative breast cancer. Cancer Treat Rev. 2024;123:102669. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102669.","journal-title":"Cancer Treat Rev"},{"key":"4440_CR5","doi-asserted-by":"publisher","first-page":"103280","DOI":"10.1016\/j.critrevonc.2021.103280","volume":"160","author":"R Torrisi","year":"2021","unstructured":"Torrisi R, Marrazzo E, Agostinetto E, et al. Neoadjuvant chemotherapy in hormone receptor-positive\/HER2-negative early breast cancer: when, why and what? Crit Rev Oncol Hematol. 2021;160:103280. https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103280.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4440_CR6","doi-asserted-by":"publisher","unstructured":"Chen X, Zhao Y, Wang Y, et al. Fluctuations in serum lipid levels during neoadjuvant treatment as novel predictive and prognostic biomarkers for locally advanced breast cancer: a retrospective analysis based on a prospective cohort. Lipids Health Dis. 2024;23(1):261. Published 2024 Aug 22. https:\/\/doi.org\/10.1186\/s12944-024-02140-x","DOI":"10.1186\/s12944-024-02140-x"},{"key":"4440_CR7","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.devcel.2021.04.013","volume":"56","author":"LA Broadfield","year":"2021","unstructured":"Broadfield LA, Pane AA, Talebi A, Swinnen JV, Fendt S-M. Lipid metabolism in cancer: new perspectives and emerging mechanisms. Dev Cell. 2021;56:1363\u201393. https:\/\/doi.org\/10.1016\/j.devcel.2021.04.013.","journal-title":"Dev Cell"},{"key":"4440_CR8","doi-asserted-by":"publisher","unstructured":"Ma Y, Lv M, Yuan P, Chen X, Liu Z. Dyslipidemia is associated with a poor prognosis of breast cancer in patients receiving neoadjuvant chemotherapy. BMC Cancer. 2023;23(1):208. Published 2023 Mar 4. https:\/\/doi.org\/10.1186\/s12885-023-10683-y","DOI":"10.1186\/s12885-023-10683-y"},{"key":"4440_CR9","doi-asserted-by":"publisher","unstructured":"Goto W, Kashiwagi S, Takada K, et al. Clinical verification of the relationship between serum lipid metabolism and immune activity in breast cancer patients treated with neoadjuvant chemotherapy. Eur J Med Res. 2023;28(1):2. Published 2023 Jan 2. https:\/\/doi.org\/10.1186\/s40001-022-00964-w","DOI":"10.1186\/s40001-022-00964-w"},{"issue":"1","key":"4440_CR10","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12885-023-10683-y","volume":"23","author":"Y Ma","year":"2023","unstructured":"Ma Y, Lv M, Yuan P, Chen X, Liu Z. Dyslipidemia is associated with a poor prognosis of breast cancer in patients receiving neoadjuvant chemotherapy. BMC Cancer. 2023;23(1):208. https:\/\/doi.org\/10.1186\/s12885-023-10683-y.","journal-title":"BMC Cancer"},{"key":"4440_CR11","doi-asserted-by":"publisher","unstructured":"Faur IF, Dobrescu A, Clim IA, et al. Lipid Metabolism and Breast Cancer: A Narrative Review of the Prognostic Implications and Chemotherapy-Induced Dyslipidemia. Life (Basel). 2025;15(5):689. Published 2025 Apr 23. https:\/\/doi.org\/10.3390\/life15050689","DOI":"10.3390\/life15050689"},{"issue":"20","key":"4440_CR12","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond M, Allison KH, Harvey BE, Mangu PB, Bartlett JM, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018;36(20):2105\u201322. https:\/\/doi.org\/10.1200\/JCO.2018.77.8738.","journal-title":"J Clin Oncol"},{"issue":"7","key":"4440_CR13","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/jnci\/djaa201","volume":"113","author":"TO Nielsen","year":"2021","unstructured":"Nielsen TO, Leung S, Rimm DL, et al. Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in breast cancer working group. J Natl Cancer Inst. 2021;113(7):808\u201319.","journal-title":"J Natl Cancer Inst"},{"key":"4440_CR14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.21037\/tbcr-24-31","volume":"5","author":"J Li","year":"2024","unstructured":"Li J, Hao C, Wang K, Zhang J, Chen J, Liu Y, et al. Chinese Society of Clinical Oncology (CSCO) breast cancer guidelines 2024. Transl Breast Cancer Res. 2024;5:18. https:\/\/doi.org\/10.21037\/tbcr-24-31.","journal-title":"Transl Breast Cancer Res"},{"key":"4440_CR15","doi-asserted-by":"publisher","unstructured":"Wu J, Fan D, Shao Z, Xu B, Ren G, Jiang Z, Wang Y, Jin F, Zhang J, Zhang Q, Ma F, Ma J, Wang Z, Wang S, Wang X, Wang S, Wang H, Wang T, Wang X, Wang J, Wang J, Wang B, Fu L, Li H, Shi Y, Gan L, Liu Y, Liu J, Liu Z, Liu Q, Sun Q, Cheng W, Yu K, Tong Z, Wu X, Song C, Zhang J, Zhang J, Li J, Li B, Li M, Li H, Yang W, Yang H, Yang B, Bu H, Shen J, Shen Z, Chen Y, Chen C, Pang D, Fan Z, Zheng Y, Yu X, Liu G, Hu X, Ling Y, Tang J, Yin Y, Geng C, Yuan P, Gu Y, Chang C, Cao X, Sheng Y, Huang Y, Huang J, Peng W, Zeng X, Xie Y, Liao N; Committee of Breast Cancer Society, Chinese Anti-Cancer Association. CACA Guidelines for Holistic Integrative Management of Breast Cancer. Holist Integr Oncol. 2022;1(1):7. https:\/\/doi.org\/10.1007\/s44178-022-00007-8. Epub 2022 Jul 5.","DOI":"10.1007\/s44178-022-00007-8"},{"key":"4440_CR16","doi-asserted-by":"publisher","unstructured":"Bhatnagar R, Dixit NM, Yang EH, Sallam T. Cancer therapy's impact on lipid metabolism: Mechanisms and future avenues. Front Cardiovasc Med. 2022;9:925816. Published 2022 Aug 9. https:\/\/doi.org\/10.3389\/fcvm.2022.925816","DOI":"10.3389\/fcvm.2022.925816"},{"key":"4440_CR17","doi-asserted-by":"publisher","first-page":"114725","DOI":"10.1016\/j.bcp.2021.114725","volume":"196","author":"H Zou","year":"2022","unstructured":"Zou H, Yang N, Zhang X, Chen HW. ROR\u03b3 is a context-specific master regulator of cholesterol biosynthesis and an emerging therapeutic target in cancer and autoimmune diseases. Biochem Pharmacol. 2022;196:114725. https:\/\/doi.org\/10.1016\/j.bcp.2021.114725.","journal-title":"Biochem Pharmacol"},{"key":"4440_CR18","doi-asserted-by":"publisher","unstructured":"Ma L, Vidana Gamage HE, Tiwari S, et al. The liver X receptor is selectively modulated to differentially alter female mammary metastasis-associated myeloid cells. Endocrinology. 2022;163(7):bqac072. https:\/\/doi.org\/10.1210\/endocr\/bqac072","DOI":"10.1210\/endocr\/bqac072"},{"issue":"2","key":"4440_CR19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1182\/blood.2021012788","volume":"139","author":"A Brendolan","year":"2022","unstructured":"Brendolan A, Russo V. Targeting cholesterol homeostasis in hematopoietic malignancies. Blood. 2022;139(2):165\u201376. https:\/\/doi.org\/10.1182\/blood.2021012788.","journal-title":"Blood"},{"key":"4440_CR20","doi-asserted-by":"publisher","unstructured":"Li J, Guo Y, Zhang W, et al. Cholesterol metabolism: A strategy for overcoming drug resistance in tumors. Biochem Pharmacol. Published online May 10, 2025. https:\/\/doi.org\/10.1016\/j.bcp.2025.116974","DOI":"10.1016\/j.bcp.2025.116974"},{"issue":"10","key":"4440_CR21","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1161\/ATVBAHA.120.315037","volume":"40","author":"H Low","year":"2020","unstructured":"Low H, Mukhamedova N, Capettini LDSA, et al. Cholesterol efflux-independent modification of lipid rafts by AIBP (apolipoprotein A-I binding protein). Arterioscler Thromb Vasc Biol. 2020;40(10):2346\u201359. https:\/\/doi.org\/10.1161\/ATVBAHA.120.315037.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"4440_CR22","doi-asserted-by":"publisher","first-page":"e235834","DOI":"10.1001\/jamanetworkopen.2023.5834","volume":"6","author":"S Shubeck","year":"2023","unstructured":"Shubeck S, Zhao F, Howard FM, Olopade OI, Huo D. Response to treatment, racial and ethnic disparity, and survival in patients with breast cancer undergoing neoadjuvant chemotherapy in the US. JAMA Netw Open. 2023;6(3):e235834. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.5834.","journal-title":"JAMA Netw Open"},{"issue":"10","key":"4440_CR23","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1159\/000526155","volume":"100","author":"HJ Choi","year":"2022","unstructured":"Choi HJ, Lee JH, Jung CS, et al. Factors affecting pathologic complete remission in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer receiving neoadjuvant chemotherapy. Oncology. 2022;100(10):529\u201335. https:\/\/doi.org\/10.1159\/000526155.","journal-title":"Oncology"},{"issue":"7","key":"4440_CR24","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1055\/a-0642-9462","volume":"78","author":"P Gass","year":"2018","unstructured":"Gass P, Untch M, M\u00fcller V, et al. Using probability for pathological complete response (pCR) as a decision support marker for neoadjuvant chemotherapy in HER2 negative breast cancer patients - a survey among physicians. Geburtshilfe Frauenheilkd. 2018;78(7):707\u201314. https:\/\/doi.org\/10.1055\/a-0642-9462.","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"4440_CR25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ejca.2022.09.017","volume":"176","author":"A de Nonneville","year":"2022","unstructured":"de Nonneville A, Houvenaeghel G, Cohen M, et al. Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers. Eur J Cancer. 2022;176:181\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2022.09.017.","journal-title":"Eur J Cancer"},{"key":"4440_CR26","doi-asserted-by":"publisher","first-page":"817","DOI":"10.2147\/IJGM.S273056","volume":"13","author":"L Xu","year":"2020","unstructured":"Xu L, Dong Q, Long Y, Tang X, Zhang N, Lu K. Dynamic changes of blood lipids in breast cancer patients after (Neo)adjuvant chemotherapy: a retrospective observational study. Int J Gen Med. 2020;13:817\u201323. https:\/\/doi.org\/10.2147\/IJGM.S273056.","journal-title":"Int J Gen Med"},{"issue":"7","key":"4440_CR27","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.clbc.2024.05.001","volume":"24","author":"M Liu","year":"2024","unstructured":"Liu M, Xiang Q, Dai F, Yuan Y, Wu Z, Xiang T. Comparison of the pathological complete response rate and survival between HER2-low and HER2-zero breast cancer in neoadjuvant chemotherapy setting: a systematic review and meta-analysis. Clin Breast Cancer. 2024;24(7):575-584.e1. https:\/\/doi.org\/10.1016\/j.clbc.2024.05.001.","journal-title":"Clin Breast Cancer"},{"issue":"7","key":"4440_CR28","doi-asserted-by":"publisher","first-page":"e0305222","DOI":"10.1371\/journal.pone.0305222","volume":"19","author":"C Godina","year":"2024","unstructured":"Godina C, Khazaei S, Belting M, et al. High Caveolin-1 mRNA expression in triple-negative breast cancer is associated with an aggressive tumor microenvironment, chemoresistance, and poor clinical outcome. PLoS ONE. 2024;19(7):e0305222. https:\/\/doi.org\/10.1371\/journal.pone.0305222.","journal-title":"PLoS ONE"},{"issue":"1","key":"4440_CR29","doi-asserted-by":"publisher","first-page":"4279","DOI":"10.1038\/s41467-020-17645-z","volume":"11","author":"J Vykoukal","year":"2020","unstructured":"Vykoukal J, Fahrmann JF, Gregg JR, et al. Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancer. Nat Commun. 2020;11(1):4279. https:\/\/doi.org\/10.1038\/s41467-020-17645-z.","journal-title":"Nat Commun"},{"key":"4440_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.mce.2017.09.021","volume":"466","author":"ER Nelson","year":"2018","unstructured":"Nelson ER. The significance of cholesterol and its metabolite, 27-hydroxycholesterol in breast cancer. Mol Cell Endocrinol. 2018;466:73\u201380. https:\/\/doi.org\/10.1016\/j.mce.2017.09.021.","journal-title":"Mol Cell Endocrinol"},{"issue":"8","key":"4440_CR31","doi-asserted-by":"publisher","first-page":"BSR20240444","DOI":"10.1042\/BSR20240444","volume":"44","author":"A Mu\u00f1oz-Ayala","year":"2024","unstructured":"Mu\u00f1oz-Ayala A, Chimal-Vega B, Seraf\u00edn-Higuera N, et al. Tamoxifen metabolites treatment promotes ER\u03b1+ transition to triple negative phenotype in vitro, effects of LDL in chemoresistance. Biosci Rep. 2024;44(8):BSR20240444. https:\/\/doi.org\/10.1042\/BSR20240444.","journal-title":"Biosci Rep"},{"key":"4440_CR32","doi-asserted-by":"publisher","unstructured":"Guan Y, Liu X, Yang Z, et al. PCSK9 Promotes LDLR Degradation by Preventing SNX17-Mediated LDLR Recycling. Circulation. Published online March 12, 2025 https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.072336","DOI":"10.1161\/CIRCULATIONAHA.124.072336"},{"issue":"6","key":"4440_CR33","doi-asserted-by":"publisher","first-page":"4169","DOI":"10.1007\/s10895-024-03785-8","volume":"35","author":"RNE Gammal","year":"2025","unstructured":"Gammal RNE, Elmansi H, El-Emam AA, Belal F, Hammouda MEA. In-vitro study of the binding of atorvastatin with adenine using multi-spectroscopic approaches. J Fluoresc. 2025;35(6):4169\u201381. https:\/\/doi.org\/10.1007\/s10895-024-03785-8.","journal-title":"J Fluoresc"},{"key":"4440_CR34","doi-asserted-by":"publisher","first-page":"216763","DOI":"10.1016\/j.canlet.2024.216763","volume":"588","author":"BY Han","year":"2024","unstructured":"Han BY, Chen C, Luo H, et al. Clinical sequencing defines the somatic and germline mutation landscapes of Chinese HER2-low breast cancer. Cancer Lett. 2024;588:216763. https:\/\/doi.org\/10.1016\/j.canlet.2024.216763.","journal-title":"Cancer Lett"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-026-04440-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-026-04440-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-026-04440-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T02:47:42Z","timestamp":1779936462000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12905-026-04440-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4440"],"URL":"https:\/\/doi.org\/10.1186\/s12905-026-04440-z","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was conducted in accordance with the standards set out in the Declaration of Helsinki. This study was approved by the Ethics Review Committee of the Affiliated Huizhou Hospital, Guangzhou Medical University (Research Approval Number: 2024-KY-112\u201301). Based on the retrospective nature of the study, the need for written informed consent was waived by the Ethics Review Committee of the Affiliated Huizhou Hospital, Guangzhou Medical University. However, all participants had the opportunity to opt-out on a homepage of the Ethics Review Committee of the Affiliated Huizhou Hospital, Guangzhou Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"263"}}